Marker Therapeutics, Inc.
MRKR
$1.21
-$0.07-5.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.10M | 1.23M | 861.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1.10M | 1.23M | 861.20K |
| Cost of Revenue | 1.48M | 2.84M | 2.14M | 2.35M | 4.18M |
| Gross Profit | -1.48M | -2.84M | -1.04M | -1.11M | -4.18M |
| SG&A Expenses | 1.14M | 1.23M | 846.60K | 1.02M | 945.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.62M | 4.07M | 2.99M | 3.37M | 5.12M |
| Operating Income | -2.62M | -4.07M | -1.88M | -2.14M | -5.12M |
| Income Before Tax | -1.83M | -3.18M | -1.72M | -2.00M | -4.02M |
| Income Tax Expenses | -- | -- | -15.20K | -- | -- |
| Earnings from Continuing Operations | -1.83M | -3.18M | -1.70M | -2.00M | -4.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.83M | -3.18M | -1.70M | -2.00M | -4.02M |
| EBIT | -2.62M | -4.07M | -1.88M | -2.14M | -5.12M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.09 | -0.16 | -0.09 | -0.12 | -0.29 |
| Normalized Basic EPS | -0.06 | -0.10 | -0.06 | -0.07 | -0.18 |
| EPS Diluted | -0.09 | -0.16 | -0.09 | -0.12 | -0.29 |
| Normalized Diluted EPS | -0.06 | -0.10 | -0.06 | -0.07 | -0.18 |
| Average Basic Shares Outstanding | 19.31M | 19.31M | 19.36M | 16.76M | 13.96M |
| Average Diluted Shares Outstanding | 19.31M | 19.31M | 19.36M | 16.76M | 13.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |